IDEXX Laboratories, Inc. $IDXX Shares Bought by Liontrust Investment Partners LLP

Liontrust Investment Partners LLP grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,337 shares of the company’s stock after purchasing an additional 26,557 shares during the quarter. IDEXX Laboratories makes up 1.4% of Liontrust Investment Partners LLP’s portfolio, making the stock its 22nd largest holding. Liontrust Investment Partners LLP’s holdings in IDEXX Laboratories were worth $99,644,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in IDXX. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories during the third quarter valued at $26,000. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $26,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $30,000. Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories in the 3rd quarter valued at about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its position in IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $558.80 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The firm’s 50-day simple moving average is $557.37 and its 200 day simple moving average is $590.62. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.08 billion, a P/E ratio of 41.15, a P/E/G ratio of 3.12 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group cut their price target on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a report on Monday. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $749.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.